Addex Therapeutics (NASDAQ:ADXN) Issues Earnings Results

Addex Therapeutics (NASDAQ:ADXN) posted its earnings results on Thursday. The company reported ($1.50) EPS for the quarter, FiscalAI reports. The business had revenue of $0.01 million for the quarter.

Addex Therapeutics Stock Performance

Shares of NASDAQ:ADXN opened at $6.00 on Thursday. The stock’s 50-day moving average is $6.71 and its 200-day moving average is $7.14. The company has a market cap of $7.38 million, a P/E ratio of -1.05 and a beta of 1.48. Addex Therapeutics has a 52-week low of $5.41 and a 52-week high of $12.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.